Suppr超能文献

外耳道原发性鳞状细胞癌的系统回顾:基于 T 分期的生存结果及新分类建议。

A systematic review of the primary squamous cell carcinoma of the external auditory canal: survival outcome based on T-staging and proposal of a new classification.

机构信息

ENT Service, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Neurosurgery Service and Gamma Knife Center, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.

出版信息

J Laryngol Otol. 2021 Feb;135(2):96-103. doi: 10.1017/S0022215121000323. Epub 2021 Feb 11.

Abstract

OBJECTIVE

This study aimed to provide a systematic review on survival outcome based on Pittsburgh T-staging for patients with primary external auditory canal squamous cell carcinoma.

METHOD

This study was a systematic review in compliance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines performed until January 2018; pertinent studies were screened. Quality of evidence was assessed using the grading of recommendation, assessment, development and evaluation working group system.

RESULTS

Eight articles were chosen that reported on 437 patients with external auditory carcinoma. The 5-year overall survival rate was 53.0 per cent. The pooled proportion of survivors at 5 years for T1 tumours was 88.4 per cent and for T2 tumours was 88.6 per cent. For the combined population of T1 and T2 cancer patients, it was 84.5 per cent. For T3 and T4 tumours, it was 53.3 per cent and 26.8 per cent, respectively, whereas for T3 and T4 tumours combined, it was 40.4 per cent. Individual analysis of 61 patients with presence of cervical nodes showed a poor survival rate.

CONCLUSION

From this review, there was not any significant difference found in the survival outcome between T1 and T2 tumours. A practical classification incorporating nodal status that accurately stratifies patients was proposed.

摘要

目的

本研究旨在对原发性外耳道鳞状细胞癌患者的匹兹堡 T 分期生存结果进行系统评价。

方法

本研究为 2018 年 1 月前完成的符合系统评价和荟萃分析报告的首选项目的系统评价;筛选了相关研究。使用推荐分级评估、制定与评价工作组系统评估证据质量。

结果

选择了 8 篇报道了 437 例外耳道癌患者的文章。5 年总生存率为 53.0%。T1 肿瘤 5 年生存率的合并比例为 88.4%,T2 肿瘤为 88.6%。T1 和 T2 癌症患者的合并比例为 84.5%。T3 和 T4 肿瘤的生存率分别为 53.3%和 26.8%,而 T3 和 T4 肿瘤合并的生存率为 40.4%。61 例颈部淋巴结阳性患者的个体分析显示生存率较差。

结论

本研究中,T1 和 T2 肿瘤的生存结果无显著差异。提出了一种实用的分类方法,该方法纳入了淋巴结状态,可以准确分层患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验